J
Joel Shapiro
Researcher at Erasmus University Rotterdam
Publications - 41
Citations - 3253
Joel Shapiro is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Chemoradiotherapy & Neoadjuvant therapy. The author has an hindex of 22, co-authored 37 publications receiving 2559 citations. Previous affiliations of Joel Shapiro include Rochester General Health System & Utrecht University.
Papers
More filters
Journal ArticleDOI
Typical and Atypical Chronic Lymphocytic Leukemia Differ Clinically and Immunophenotypically
John L. Frater,Karen F. McCarron,Jeffrey P. Hammel,Joel Shapiro,Michael L. Miller,Raymond R. Tubbs,James Pettay,Eric D. Hsi +7 more
TL;DR: Atypical morphologic features in CLL seem to be a marker of aggressive clinical behavior and can be distinguished from typical CLL morphologically, clinically, and immunophenotypically.
Journal ArticleDOI
Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa
Joel Shapiro,Fiebo J.W. ten Kate,Pieter van Hagen,Katharina Biermann,Bas P. L. Wijnhoven,J. Jan B. van Lanschot +5 more
TL;DR: After nCRT for esophageal cancer, both the mucosa and the submucosa show frequent residual malignant involvement and the overall regression pattern is most frequently a mixed pattern of both concentric regression and regression toward the lumen.
Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer
Joel Shapiro,P. M. van Hagen,Hester F. Lingsma,B. P. L. Wijnhoven,Katharina Biermann,F. J. W. Ten Kate,Ewout W. Steyerberg,A. van der Gaast,J. J. B. van Lanschot,Johannes J. Bonenkamp +9 more
Journal ArticleDOI
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: Results from the randomized CROSS trial
Bo Jan Noordman,Mathilde G. E. Verdam,Sjoerd M. Lagarde,Joel Shapiro,Maarten C.C.M. Hulshof,M. I. van Berge Henegouwen,B. P. L. Wijnhoven,G.A.P. Nieuwenhuijzen,Johannes J. Bonenkamp,M. A. Cuesta,J.Th.M. Plukker,E. J. Spillenaar Bilgen,Ewout W. Steyerberg,Ewout W. Steyerberg,A. van der Gaast,Mirjam A. G. Sprangers,J. J. B. van Lanschot +16 more
TL;DR: The view that nCRT according to CROSS can be considered as a standard of care as well as the earlier reported improvement in survival and the absence of impact on short-term HRQOL is supported.
Journal ArticleDOI
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy.
TL;DR: A 31-year-old white male presented to the emergency room in January 2005 with three-day history of fevers, chills, and malaise, and was started on high dose steroids with subsequent normalization of the CBC, LDH and the liver enzymes.